Article thumbnail

Modernizing Surveillance of Antituberculosis Drug Resistance: From Special Surveys to Routine Testing

By Matteo Zignol, Wayne van Gemert, Dennis Falzon, Ernesto Jaramillo, Léopold Blanc and Mario Raviglione

Abstract

Availability of new diagnostic tools and global commitment towards universal access to tuberculosis care will accelerate capacity of resource-limited countries to monitor anti-tuberculosis drug resistance. Special surveys will be replaced by routine surveillance of drug resistance linked to patient care

Topics: Viewpoints
Publisher: Oxford University Press
OAI identifier: oai:pubmedcentral.nih.gov:3062546
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by crosssectional survey for use in low resource settings. Antivir Ther 2008; 13(Suppl 2):37–48.
  2. (2004). Anti-tuberculosis drug resistance in the world: t h eW
  3. (1997). Anti-tuberculosis drug resistance in the world: the WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance. WHO,
  4. (2010). Available at: http://www.who.int/tb/publications/factsheet_expand_tb.pdf.
  5. (2011). Drug susceptibility testing proficiency in the network of supranational tuberculosis reference laboratories. Int J Tuberc Lung Dis
  6. Drugresistant tuberculosis: review of the worldwide situation and the WHO/IUATLD Global Surveillance Project. International Union Against Tuberculosis and Lung Disease. Clin Infect Dis 1997; 24(Suppl 1):S121–30.
  7. Estimating the magnitude and direction of bias in tuberculosis drug resistance surveys conducted only in the public sector: a simulation study.
  8. (2011). Evaluation of the GenotypeMTBDRplus Assay as a tool for drug-resistance surveys. Int J Tuberc Lung Dis
  9. (2006). Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet
  10. For the Global Project on Anti-Tuberculosis Anti-TB Drug Resistance Surveillance d
  11. HIV infection and multidrug-resistant tuberculosis: the perfect storm. J Infect Dis 2007; 196(Suppl 1):S86–107.
  12. (2008). Implementation of the tuberculosis drug resistance survey in Tanzania. MC Public Health
  13. (2009). Is HIV infection a risk factor for multi-drug resistant tuberculosis? A systematic review. LoS One
  14. (2009). Mechanisms of drug resistance in Mycobacterium tuberculosis.
  15. (2008). Organization (WHO). Antituberculosis drug resistance in the world: the WHO/IUATLD Global Project on AntiTuberculosis Drug Resistance Surveillance. Fourth global report.
  16. (2000). Organization (WHO). Antituberculosis drug resistance in the world: the WHO/IUATLD Global Project on AntiTuberculosis Drug Resistance Surveillance. Report 2: Prevalence and trends.
  17. (2010). Organization (WHO). Global Tuberculosis Control
  18. (2009). Organization (WHO). Green Light Committee Initiative of the Working Group on
  19. (2010). Organization (WHO). Multidrug and extensively drug-resistant TB (M/XDR-TB):
  20. Organization. Guidelines for surveillance of drug resistance in tuberculosis. 1st ed.
  21. (2009). Organization. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB): Policy Statement.
  22. (2007). Patients with previously treated tuberculosis no longer neglected. Clin Infect Dis
  23. (2009). Prevention and control of multidrug-resistant tuberculosis and extensively drug-resistant tuberculosis In: Sixty-Second World Health Assembly,
  24. (1997). Quality assurance programme for drug susceptibility testing of Mycobacterium tuberculosis in the WHO/ IUATLD Supranational Laboratory Network: first round of proficiency testing. Int J Tuberc Lung Dis
  25. (2010). Rapid molecular detection of tuberculosis and rifampin resistance.
  26. (2008). Rapid molecular screening for multidrug-resistant tuberculosis in a highvolume public health laboratory in South Africa. Am J Respir Crit Care Med
  27. (2009). Slow elimination of multidrug-resistant tuberculosis. Sci Transl Med
  28. (2003). Source and treatment outcomes of tuberculosis re-treatment cases under the Revised National Tuberculosis Control Programme in
  29. (2009). Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLoS Med
  30. (1948). Streptomycin treatment of pulmonary tuberculosis: a Medical Research Council investigation. BMJ
  31. Surveillance for MDR-TB: is there an obligation to ensure treatment for individuals identified with MDR-TB?
  32. The prevalence of drug-resistant tubercle bacilli in untreated patients with pulmonary tuberculosis: a national survey, 1955–1956. Tubercle (Lond.)
  33. (2006). Tuberculosis control: progress and long-term planning. In: World Health Assembly First Special Session,
  34. (1998). Tuberculosis patients and practitioners in private clinics in India. Int J Tuberc Lung Dis
  35. World Health Organization (WHO). ‘‘What is the role of mycobacterial culture in diagnosis and case definition?’’ In: Toman’s tuberculosis, case detection, treatment monitoring—questions and answers.
  36. (2009). World Health Organization (WHO). Guidelines for surveillance of drug resistance in tuberculosis. 4th ed.
  37. (2009). World Health Organization (WHO). Treatment of tuberculosis guidelines. 4th ed.